PMID- 24648723 OWN - NLM STAT- MEDLINE DCOM- 20140929 LR - 20221207 IS - 1178-1998 (Electronic) IS - 1176-9092 (Print) IS - 1176-9092 (Linking) VI - 9 DP - 2014 TI - Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. PG - 411-8 LID - 10.2147/CIA.S58830 [doi] AB - BACKGROUND: Selective serotonin reuptake inhibitors improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of selective serotonin reuptake inhibitors on cognition and serum BDNF levels in patients with vascular dementia are largely unknown. We performed an open-label study to investigate the effects of fluoxetine, a selective serotonin reuptake inhibitor, on cognition and serum BDNF levels in patients with vascular dementia. METHODS: Fifty patients with vascular dementia were randomly allocated to receive fluoxetine (20 mg/day; n=25) or no fluoxetine (control group; n=25) for 12 weeks. Both groups received secondary prevention of stroke. Serum BDNF level, Mini-Mental State Examination (MMSE) score, Ten-Point Clock Drawing score, and Digit Span Test and Verbal Fluency Test scores were measured at baseline and at week 12 in the both groups. RESULTS: The baseline serum BDNF level correlated significantly with the MMSE score. MMSE score, Ten-Point Clock Drawing score, and serum BDNF level increased significantly in the fluoxetine group but not in the control group. The increase in serum BDNF level correlated with the increase in MMSE score in the fluoxetine group. CONCLUSION: Fluoxetine may potentially improve cognition in patients with vascular dementia and requires further investigation. BDNF may play an important role in cognitive recovery. FAU - Liu, Xuan AU - Liu X AD - Department of Neurology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China ; Department of Neurology, Xiangyang Central Hospital, Medical College, Hubei University of Arts and Science, Xiangyang, Hubei, People's Republic of China. FAU - Zhang, Junjian AU - Zhang J AD - Department of Neurology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China. FAU - Sun, Dong AU - Sun D AD - Department of Neurology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China. FAU - Fan, Yuanteng AU - Fan Y AD - Department of Neurology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China. FAU - Zhou, Hongbin AU - Zhou H AD - Department of Neurology, Xiangyang Central Hospital, Medical College, Hubei University of Arts and Science, Xiangyang, Hubei, People's Republic of China. FAU - Fu, Binfang AU - Fu B AD - Department of Neurology, Xiangyang Central Hospital, Medical College, Hubei University of Arts and Science, Xiangyang, Hubei, People's Republic of China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20140310 PL - New Zealand TA - Clin Interv Aging JT - Clinical interventions in aging JID - 101273480 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Serotonin Uptake Inhibitors) RN - 01K63SUP8D (Fluoxetine) SB - IM MH - Aged MH - Brain-Derived Neurotrophic Factor/*blood MH - Cognition/*drug effects MH - Dementia, Vascular/blood/*drug therapy MH - Female MH - Fluoxetine/*therapeutic use MH - Humans MH - Male MH - Neuropsychological Tests MH - Selective Serotonin Reuptake Inhibitors/*therapeutic use PMC - PMC3956624 OTO - NOTNLM OT - brain-derived neurotrophic factor OT - cognition OT - fluoxetine OT - improvement OT - neuroplasticity OT - vascular dementia EDAT- 2014/03/22 06:00 MHDA- 2014/09/30 06:00 PMCR- 2014/03/10 CRDT- 2014/03/21 06:00 PHST- 2014/03/21 06:00 [entrez] PHST- 2014/03/22 06:00 [pubmed] PHST- 2014/09/30 06:00 [medline] PHST- 2014/03/10 00:00 [pmc-release] AID - cia-9-411 [pii] AID - 10.2147/CIA.S58830 [doi] PST - epublish SO - Clin Interv Aging. 2014 Mar 10;9:411-8. doi: 10.2147/CIA.S58830. eCollection 2014.